This is a Validated Antibody Database (VAD) review about mouse Kras, based on 53 published articles (read how Labome selects the articles), using Kras antibody in all methods. It is aimed to help Labome visitors find the most suited Kras antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
Kras synonym: AI929937; K-Ras; K-Ras 2; K-ras; Ki-ras; Kras-2; Kras2; c-K-ras; c-Ki-ras; p21B; ras

Knockout validation
Santa Cruz Biotechnology
mouse monoclonal (F234)
  • western blot knockout validation; mouse; fig 1
In order to explore how different Ras isoforms contribute to transformation, Santa Cruz Biotechnology Kras antibody (Santa, sc-30) was used in western blot knockout validation on mouse samples (fig 1). Mol Cell Biol (2007) ncbi
Santa Cruz Biotechnology
mouse monoclonal (F234)
  • western blot; human; 1:500; loading ...; fig s1i
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples at 1:500 (fig s1i). Nat Commun (2020) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 9g
Santa Cruz Biotechnology Kras antibody (Santa cruz, sc-30) was used in western blot on human samples (fig 9g). Nat Commun (2020) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:500; loading ...; fig 4f
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples at 1:500 (fig 4f). Nature (2019) ncbi
mouse monoclonal (F234)
  • western blot; mouse; 1:1000; loading ...; fig s1d
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on mouse samples at 1:1000 (fig s1d). Nat Commun (2019) ncbi
mouse monoclonal (F234)
  • western blot; mouse; loading ...; fig 3d
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on mouse samples (fig 3d). Nature (2019) ncbi
mouse monoclonal (F234)
  • western blot; human; loading ...; fig 3e
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples (fig 3e). Exp Mol Med (2018) ncbi
mouse monoclonal (F234)
  • western blot; mouse; fig 1a
Santa Cruz Biotechnology Kras antibody (SantaCruz, sc-30) was used in western blot on mouse samples (fig 1a). Cell (2018) ncbi
mouse monoclonal (F234)
  • immunoprecipitation; human; loading ...; tbl 1
  • immunocytochemistry; human; loading ...; tbl 1
  • western blot; human; fig 1d
In order to evaluation isoform- and mutation-specific RAS antibodies, Santa Cruz Biotechnology Kras antibody (Santa Cruz, SC-30) was used in immunoprecipitation on human samples (tbl 1), in immunocytochemistry on human samples (tbl 1) and in western blot on human samples (fig 1d). Sci Signal (2017) ncbi
mouse monoclonal (F234)
  • western blot; human; loading ...; fig 2c
In order to study the effect of GNAQ mutations and GNA11/MAPK pathway activation in uveal melanoma, Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples (fig 2c). Cancer Cell (2017) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:200; loading ...; fig 3c
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples at 1:200 (fig 3c). Cell Death Differ (2017) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 5a
Santa Cruz Biotechnology Kras antibody (Santa Cruz, Sc-30) was used in western blot on human samples (fig 5a). Apoptosis (2017) ncbi
mouse monoclonal (F234)
  • western blot; human; loading ...; fig 3b; 4a
  • western blot; mouse; loading ...; fig 3e
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples (fig 3b; 4a) and in western blot on mouse samples (fig 3e). BMC Cancer (2017) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:500; loading ...; fig 2d
In order to report FOSL1 as a common transcriptional signature across mutant KRAS cancers of distinct tissue origin, Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples at 1:500 (fig 2d). Nat Commun (2017) ncbi
mouse monoclonal (F132)
  • western blot; human; loading ...; fig 7a
In order to explore the role of the S100A7 in oral squamous cell carcinoma, Santa Cruz Biotechnology Kras antibody (Santa Cruz, S-32) was used in western blot on human samples (fig 7a). Cancer Gene Ther (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; loading ...; fig 7a
In order to explore the role of the S100A7 in oral squamous cell carcinoma, Santa Cruz Biotechnology Kras antibody (Santa Cruz, S-30) was used in western blot on human samples (fig 7a). Cancer Gene Ther (2016) ncbi
mouse monoclonal (F234)
  • immunocytochemistry; human; loading ...; fig 3d
  • western blot; human; loading ...; fig 6h
Santa Cruz Biotechnology Kras antibody (Santa Cruz, Sc-30) was used in immunocytochemistry on human samples (fig 3d) and in western blot on human samples (fig 6h). Cell Death Discov (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; loading ...; fig 1b
In order to demonstrate that both Ras and Rap1 are required for cyclic adenosine monophosphate signaling to extracellular signal-regulated kinase, Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples (fig 1b). J Biol Chem (2016) ncbi
mouse monoclonal (F234)
  • western blot; mouse; 1:1000
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on mouse samples at 1:1000. elife (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:1000; fig s2
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples at 1:1000 (fig s2). Cell Death Dis (2016) ncbi
mouse monoclonal (F234)
  • western blot; mouse; fig 7
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on mouse samples (fig 7). PLoS ONE (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 2 a',' b
In order to assess the contribution of MEK5/ERK5 signaling in the sensitivity of colon cancer cells to 5-fluorouracil, Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples (fig 2 a',' b). Oncotarget (2016) ncbi
rat monoclonal (259)
  • immunoprecipitation; human; fig 6
  • western blot; human; fig 6
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-35l) was used in immunoprecipitation on human samples (fig 6) and in western blot on human samples (fig 6). Oncotarget (2016) ncbi
mouse monoclonal (C-4)
  • western blot; mouse; fig 1
  • western blot; human; fig 1
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-166691) was used in western blot on mouse samples (fig 1) and in western blot on human samples (fig 1). Cell Commun Signal (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:1000; fig 2
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples at 1:1000 (fig 2). Nat Commun (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 1
Santa Cruz Biotechnology Kras antibody (santa Cruz, sc-30) was used in western blot on human samples (fig 1). Oncotarget (2016) ncbi
mouse monoclonal (F234)
  • western blot; mouse; loading ...; fig 1a
In order to present the role of Kras in B cell lymphopoiesis, Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on mouse samples (fig 1a). J Immunol (2016) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 1
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 6
Santa Cruz Biotechnology Kras antibody (santa Cruz, sc-30) was used in western blot on human samples (fig 6). PLoS ONE (2015) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:200; fig 1
Santa Cruz Biotechnology Kras antibody (santa Cruz, sc-30) was used in western blot on human samples at 1:200 (fig 1). PLoS ONE (2015) ncbi
mouse monoclonal (F234)
  • western blot; mouse; 1:1000
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on mouse samples at 1:1000. Cancer Res (2015) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:25; fig 2c
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, F234) was used in western blot on human samples at 1:25 (fig 2c). Sci Rep (2015) ncbi
mouse monoclonal (F234)
  • western blot; rat; 1:200; loading ...; fig 3
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on rat samples at 1:200 (fig 3). Oncol Lett (2015) ncbi
mouse monoclonal (F234)
  • western blot; mouse; 1:200; fig 1
In order to assess the effect of the C118S mutation of Kras on tumorigenesis, Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on mouse samples at 1:200 (fig 1). Nat Commun (2014) ncbi
mouse monoclonal (F234)
  • western blot; human
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples . Cancer Res (2014) ncbi
mouse monoclonal (F234)
  • western blot; mouse; fig 4
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnologies, sc-30) was used in western blot on mouse samples (fig 4). Oncogene (2015) ncbi
mouse monoclonal (F234)
  • western blot; human; fig 5
Santa Cruz Biotechnology Kras antibody (santa Cruz, sc-30) was used in western blot on human samples (fig 5). Oncogene (2015) ncbi
mouse monoclonal (C-4)
  • western blot; human
Santa Cruz Biotechnology Kras antibody (Santa, sc-166691) was used in western blot on human samples . Oncogene (2014) ncbi
mouse monoclonal (F234)
  • western blot; human; 1:100; fig 6
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples at 1:100 (fig 6). Cell Death Dis (2013) ncbi
mouse monoclonal (F234)
  • western blot; human
Santa Cruz Biotechnology Kras antibody (Santa Cruz Biotechnology, sc-30) was used in western blot on human samples . Biochem J (2013) ncbi
mouse monoclonal (F234)
  • western blot; human
Santa Cruz Biotechnology Kras antibody (Santa Cruz, sc-30) was used in western blot on human samples . J Biol Chem (2013) ncbi
mouse monoclonal (F234)
  • western blot knockout validation; mouse; fig 1
In order to explore how different Ras isoforms contribute to transformation, Santa Cruz Biotechnology Kras antibody (Santa, sc-30) was used in western blot knockout validation on mouse samples (fig 1). Mol Cell Biol (2007) ncbi
Invitrogen
mouse monoclonal (RAS10)
  • western blot; human; loading ...; fig 4b
In order to discover new regulatory proteins involved in Rap1-dependent T-cell adhesion and migration., Invitrogen Kras antibody (Fisher, 10.2) was used in western blot on human samples (fig 4b). Proc Natl Acad Sci U S A (2017) ncbi
mouse monoclonal (RAS10)
  • western blot; human; loading ...; fig 1c
In order to determine a critical role of isoprenylcysteine carboxylmethyltransferase in RAS-driven cancers, Invitrogen Kras antibody (Pierce, MA1-012) was used in western blot on human samples (fig 1c). Oncogene (2017) ncbi
mouse monoclonal (RAS10)
  • immunoprecipitation; human; 1:50; loading ...; fig 1d
In order to identify Aurora kinase A as a novel Ras binding protein, Invitrogen Kras antibody (ThermoScientific, MA1-012X) was used in immunoprecipitation on human samples at 1:50 (fig 1d). Oncotarget (2017) ncbi
mouse monoclonal (RAS10)
  • western blot; human; loading ...; fig 4c
In order to show the Nogo-B receptor promotes accumulation of prenylated Ras at the plasma membrane, Invitrogen Kras antibody (Thermo Fischer Scientific, MA1-012) was used in western blot on human samples (fig 4c). Oncogene (2017) ncbi
mouse monoclonal (RAS10)
  • western blot; human; loading ...; fig 4a
In order to propose that increasing calmodulin levels enhance Myc transcriptional and oncogenic activities, Invitrogen Kras antibody (Thermo Fisher Scientific, MA1-012) was used in western blot on human samples (fig 4a). Oncotarget (2017) ncbi
mouse monoclonal (RAS10)
  • western blot; human; 1:5000; loading ...; fig 4g
In order to demonstrate the bipartite role of Hsp90 in chaperoning CRAF kinase, Invitrogen Kras antibody (Thermo Pierce, NA1-012) was used in western blot on human samples at 1:5000 (fig 4g). J Biol Chem (2016) ncbi
mouse monoclonal (RAS10)
  • western blot; mouse; fig 3c
In order to report that ezrin is required for Ras activation, Invitrogen Kras antibody (Thermo, RAS10) was used in western blot on mouse samples (fig 3c). Hum Mutat (2015) ncbi
mouse monoclonal (RAS10)
  • western blot; human; fig 1
In order to show that 8.12 is a pharmacological inhibitor of Icmt, Invitrogen Kras antibody (Pierce, MA1-012) was used in western blot on human samples (fig 1). Cancer Biol Ther (2014) ncbi
mouse monoclonal (9.13)
  • western blot; human
In order to demonstrate that miR-200c regulates KRAS, Invitrogen Kras antibody (Invitrogen, 415700) was used in western blot on human samples . Oncotarget (2014) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D2C1)
  • western blot; human; 1:1000; loading ...; fig s9d
Cell Signaling Technology Kras antibody (Cell Signaling Technology, 8955) was used in western blot on human samples at 1:1000 (fig s9d). Nat Commun (2021) ncbi
domestic rabbit monoclonal (D2C1)
  • western blot; mouse; 1:1000; loading ...; fig 7a
Cell Signaling Technology Kras antibody (Cell Signaling Technology, 8955) was used in western blot on mouse samples at 1:1000 (fig 7a). Cell Mol Gastroenterol Hepatol (2019) ncbi
domestic rabbit monoclonal (D2C1)
  • western blot; human; loading ...; fig 4b
Cell Signaling Technology Kras antibody (Cell Signaling, 8955) was used in western blot on human samples (fig 4b). J Exp Med (2019) ncbi
domestic rabbit monoclonal (D2C1)
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology Kras antibody (Cell Signaling, 8955) was used in western blot on human samples (fig 1a). elife (2018) ncbi
Articles Reviewed
  1. Shi L, Magee P, Fassan M, Sahoo S, Leong H, LEE D, et al. A KRAS-responsive long non-coding RNA controls microRNA processing. Nat Commun. 2021;12:2038 pubmed publisher
  2. Kennedy S, Jarboui M, Srihari S, Raso C, Bryan K, Dernayka L, et al. Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRASG13D. Nat Commun. 2020;11:499 pubmed publisher
  3. Kabayama H, Takeuchi M, Tokushige N, Muramatsu S, Kabayama M, Fukuda M, et al. An ultra-stable cytoplasmic antibody engineered for in vivo applications. Nat Commun. 2020;11:336 pubmed publisher
  4. Ramírez C, Hauser A, Vucic E, Bar Sagi D. Plasma membrane V-ATPase controls oncogenic RAS-induced macropinocytosis. Nature. 2019;576:477-481 pubmed publisher
  5. Bueno M, Jimenez Renard V, Samino S, Capellades J, Junza A, López Rodríguez M, et al. Essentiality of fatty acid synthase in the 2D to anchorage-independent growth transition in transforming cells. Nat Commun. 2019;10:5011 pubmed publisher
  6. Gao C, Chen G, Zhang D, Zhang J, Kuan S, Hu W, et al. PYK2 Is Involved in Premalignant Acinar Cell Reprogramming and Pancreatic Ductal Adenocarcinoma Maintenance by Phosphorylating β-CateninY654. Cell Mol Gastroenterol Hepatol. 2019;8:561-578 pubmed publisher
  7. Yao W, Rose J, Wang W, Seth S, Jiang H, Taguchi A, et al. Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. Nature. 2019;: pubmed publisher
  8. Chen H, Poran A, Unni A, Huang S, Elemento O, Snoeck H, et al. Generation of pulmonary neuroendocrine cells and SCLC-like tumors from human embryonic stem cells. J Exp Med. 2019;216:674-687 pubmed publisher
  9. Unni A, Harbourne B, Oh M, Wild S, Ferrarone J, Lockwood W, et al. Hyperactivation of ERK by multiple mechanisms is toxic to RTK-RAS mutation-driven lung adenocarcinoma cells. elife. 2018;7: pubmed publisher
  10. Lee S, Cho Y, Cha P, Yoon J, Ro E, Jeong W, et al. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab. Exp Mol Med. 2018;50:153 pubmed publisher
  11. Ambrogio C, Köhler J, Zhou Z, Wang H, Paranal R, Li J, et al. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172:857-868.e15 pubmed publisher
  12. Waters A, Ozkan Dagliyan I, Vaseva A, Fer N, Strathern L, Hobbs G, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal. 2017;10: pubmed publisher
  13. Chen X, Wu Q, Depeille P, Chen P, Thornton S, Kalirai H, et al. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma. Cancer Cell. 2017;31:685-696.e6 pubmed publisher
  14. Shen H, Xing C, Cui K, Li Y, Zhang J, Du R, et al. MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1. Cell Death Differ. 2017;24:1253-1262 pubmed publisher
  15. Taoka R, Jinesh G, Xue W, Safe S, Kamat A. CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis. 2017;22:719-729 pubmed publisher
  16. Forzati F, De Martino M, Esposito F, Sepe R, Pellecchia S, Malapelle U, et al. miR-155 is positively regulated by CBX7 in mouse embryonic fibroblasts and colon carcinomas, and targets the KRAS oncogene. BMC Cancer. 2017;17:170 pubmed publisher
  17. Vallejo A, Perurena N, Guruceaga E, Mazur P, Martínez Canarias S, Zandueta C, et al. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer. Nat Commun. 2017;8:14294 pubmed publisher
  18. Strazza M, Azoulay Alfaguter I, Peled M, Smrcka A, Skolnik E, Srivastava S, et al. PLCε1 regulates SDF-1α-induced lymphocyte adhesion and migration to sites of inflammation. Proc Natl Acad Sci U S A. 2017;114:2693-2698 pubmed publisher
  19. Lau H, Tang J, Casey P, Wang M. Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms. Oncogene. 2017;36:3934-3942 pubmed publisher
  20. Umstead M, Xiong J, Qi Q, Du Y, Fu H. Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling. Oncotarget. 2017;8:28359-28372 pubmed publisher
  21. Zhao B, Hu W, Kumar S, Gonyo P, Rana U, Liu Z, et al. The Nogo-B receptor promotes Ras plasma membrane localization and activation. Oncogene. 2017;36:3406-3416 pubmed publisher
  22. Raffeiner P, Schraffl A, Schwarz T, Röck R, Ledolter K, Hartl M, et al. Calcium-dependent binding of Myc to calmodulin. Oncotarget. 2017;8:3327-3343 pubmed publisher
  23. Dey K, Bharti R, Dey G, Pal I, Rajesh Y, Chavan S, et al. S100A7 has an oncogenic role in oral squamous cell carcinoma by activating p38/MAPK and RAB2A signaling pathway. Cancer Gene Ther. 2016;23:382-391 pubmed publisher
  24. Mitra S, Ghosh B, Gayen N, Roy J, Mandal A. Bipartite Role of Heat Shock Protein 90 (Hsp90) Keeps CRAF Kinase Poised for Activation. J Biol Chem. 2016;291:24579-24593 pubmed
  25. Jinesh G, Molina J, Huang L, Laing N, Mills G, Bar Eli M, et al. Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Cell Death Discov. 2016;2:16003 pubmed publisher
  26. Li Y, Dillon T, Takahashi M, Earley K, Stork P. Protein Kinase A-independent Ras Protein Activation Cooperates with Rap1 Protein to Mediate Activation of the Extracellular Signal-regulated Kinases (ERK) by cAMP. J Biol Chem. 2016;291:21584-21595 pubmed
  27. Weaver R, Limzerwala J, Naylor R, Jeganathan K, Baker D, van Deursen J. BubR1 alterations that reinforce mitotic surveillance act against aneuploidy and cancer. elife. 2016;5: pubmed publisher
  28. Anta B, Pérez Rodríguez A, Castro J, García Domínguez C, Ibiza S, Martínez N, et al. PGA1-induced apoptosis involves specific activation of H-Ras and N-Ras in cellular endomembranes. Cell Death Dis. 2016;7:e2311 pubmed publisher
  29. Petrova L, Gran C, Bjoras M, Doetsch P. Efficient and Reliable Production of Vectors for the Study of the Repair, Mutagenesis, and Phenotypic Consequences of Defined DNA Damage Lesions in Mammalian Cells. PLoS ONE. 2016;11:e0158581 pubmed publisher
  30. Pereira D, Simões A, Gomes S, Castro R, Carvalho T, Rodrigues C, et al. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism. Oncotarget. 2016;7:34322-40 pubmed publisher
  31. Carrero Z, Kollareddy M, Chauhan K, Ramakrishnan G, Martinez L. Mutant p53 protects ETS2 from non-canonical COP1/DET1 dependent degradation. Oncotarget. 2016;7:12554-67 pubmed publisher
  32. Hennig A, Markwart R, Wolff K, Schubert K, Cui Y, Prior I, et al. Feedback activation of neurofibromin terminates growth factor-induced Ras activation. Cell Commun Signal. 2016;14:5 pubmed publisher
  33. Tsang Y, Dogruluk T, Tedeschi P, Wardwell Ozgo J, Lu H, Espitia M, et al. Functional annotation of rare gene aberration drivers of pancreatic cancer. Nat Commun. 2016;7:10500 pubmed publisher
  34. Chung S, Moon H, Ju H, Kim D, Cho K, Ribback S, et al. Comparison of liver oncogenic potential among human RAS isoforms. Oncotarget. 2016;7:7354-66 pubmed publisher
  35. Chen Y, Zheng Y, You X, Yu M, Fu G, Su X, et al. Kras Is Critical for B Cell Lymphopoiesis. J Immunol. 2016;196:1678-85 pubmed publisher
  36. Kim J, Sato M, Choi J, Kim H, Yeh B, Larsen J, et al. Nuclear Receptor Expression and Function in Human Lung Cancer Pathogenesis. PLoS ONE. 2015;10:e0134842 pubmed publisher
  37. Brito H, Martins A, Lavrado J, Mendes E, Francisco A, Santos S, et al. Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. PLoS ONE. 2015;10:e0126891 pubmed publisher
  38. Huang L, Counter C. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S. PLoS ONE. 2015;10:e0123918 pubmed publisher
  39. Hu S, Danilov A, Godek K, Orr B, Tafe L, Rodriguez Canales J, et al. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110. Cancer Res. 2015;75:2029-38 pubmed publisher
  40. Stolze B, Reinhart S, Bulllinger L, Fröhling S, Scholl C. Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines. Sci Rep. 2015;5:8535 pubmed publisher
  41. Riecken L, Tawamie H, Dornblut C, Buchert R, Ismayel A, Schulz A, et al. Inhibition of RAS activation due to a homozygous ezrin variant in patients with profound intellectual disability. Hum Mutat. 2015;36:270-8 pubmed publisher
  42. Gao J, Du J, Wang Y, Li J, Wei L, Guo M. Synergistic effects of curcumin and bevacizumab on cell signaling pathways in hepatocellular carcinoma. Oncol Lett. 2015;9:295-299 pubmed
  43. Huang L, Carney J, Cardona D, Counter C. Decreased tumorigenesis in mice with a Kras point mutation at C118. Nat Commun. 2014;5:5410 pubmed publisher
  44. Fujimura K, Wright T, Strnadel J, Kaushal S, Metildi C, Lowy A, et al. A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer. Cancer Res. 2014;74:6671-81 pubmed publisher
  45. Song J, An N, Chatterjee S, Kistner Griffin E, Mahajan S, Mehrotra S, et al. Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene. 2015;34:3728-36 pubmed publisher
  46. Patel A, Burton D, Halvorsen K, Balkan W, Reiner T, Perez Stable C, et al. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. Oncogene. 2015;34:2586-96 pubmed publisher
  47. Lau H, Ramanujulu P, Guo D, Yang T, Wirawan M, Casey P, et al. An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo. Cancer Biol Ther. 2014;15:1280-91 pubmed publisher
  48. Kopp F, Wagner E, Roidl A. The proto-oncogene KRAS is targeted by miR-200c. Oncotarget. 2014;5:185-95 pubmed
  49. Zaganjor E, Osborne J, Weil L, Díaz Martínez L, Gonzales J, Singel S, et al. Ras regulates kinesin 13 family members to control cell migration pathways in transformed human bronchial epithelial cells. Oncogene. 2014;33:5457-66 pubmed publisher
  50. Bauckman K, Haller E, Flores I, Nanjundan M. Iron modulates cell survival in a Ras- and MAPK-dependent manner in ovarian cells. Cell Death Dis. 2013;4:e592 pubmed publisher
  51. BENTLEY C, Jurinka S, Kljavin N, Vartanian S, Ramani S, Gonzalez L, et al. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. Biochem J. 2013;452:313-20 pubmed publisher
  52. Vartanian S, BENTLEY C, Brauer M, Li L, Shirasawa S, Sasazuki T, et al. Identification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines. J Biol Chem. 2013;288:2403-13 pubmed publisher
  53. Fotiadou P, Takahashi C, Rajabi H, Ewen M. Wild-type NRas and KRas perform distinct functions during transformation. Mol Cell Biol. 2007;27:6742-55 pubmed